

CHANGE OF COMPANY AUDITOR

Melbourne, Australia – 1 October 2024: Percheron Therapeutics Limited (ASX: PER) ('Percheron' or 'the Company'), an international biotechnology company focused on the development of novel therapies for rare diseases, advises that William Buck Audit (Vic) Pty Ltd ('William Buck') has been appointed as the Company's auditors. The appointment has been formally approved by the Australian Securities & Investment Commission and, as part of the transition process, a letter of resignation has been received from Ernst & Young.

The decision to change auditors was made following a consultation process by the Board involving a review of the Company's external audit arrangements in accordance with the Company's Corporate Governance Plan and Policies. William Buck was chosen based on their reputation and industry experience.

In accordance with section 327C of the *Corporations Act 2001* (Cth), a resolution will be tabled at the Company's 2024 Annual General Meeting to confirm the appointment of William Buck as the auditor of Percheron.

The Board of Directors would like to take this opportunity to thank Ernst & Young for their professional service.

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for rare diseases. The company's lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor. Avicursen is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in December CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

*This announcement has been authorised for release to the Australian Securities Exchange
by the Board of Directors.*
